Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people's health and quality of life.

Strongly committed to neuroscience research, Roche has preclinical programs in the areas of anxiety, depression, schizophrenia and Alzheimer's disease. In addition, molecules for each of these indications are at various stages of development. Research at Roche focuses on significant unmet medical needs in the management of diseases of the central nervous system and genitourinary tract, metabolic disorders, inflammation, autoimmunity and transplantation, cancer, vascular diseases and virology.

Roche employs roughly 70,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Additional information about the Roche Group is available at www.roche.com.